Trial Profile
Phase II, Open-Label, Randomized, Controlled Study of PM060184 in Advanced, Hormone Receptor Positive, HER2 negative Breast Cancer Patients in Third or Fourth Line Setting.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Nov 2017
Price :
$35
*
At a glance
- Drugs Plocabulin (Primary)
- Indications HER2 negative breast cancer; Male breast cancer
- Focus Therapeutic Use
- Sponsors PharmaMar
- 18 Nov 2017 Status changed from recruiting to completed.
- 12 Nov 2017 This trial has been completed in Belgium, according to European Clinical Trials Database
- 23 Dec 2015 New trial record